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LETTER TO THE EDITOR
http://dx.doi.org/10.1590/S1678-9946201860043
1Universidade Federal de Pernambuco, 
Setor de Virologia, Laboratório de 
Imunopatologia Keizo Asami, Recife, 
Pernambuco, Brazil
2Fundação Oswaldo Cruz, Instituto Aggeu 
Magalhães, Departamento de Virologia e 
Terapia Experimental, Recife, Pernambuco, 
Brazil
3Instituto Federal de Educação, Ciência 
e Tecnologia do Sertão Pernambucano, 
Floresta, Pernambuco, Brazil
Correspondence to: José Valter Joaquim 
Silva Júnior 
Fundação Oswaldo Cruz, Instituto Aggeu 
Magalhães, Departamento de Virologia e 
Terapia Experimental, Cidade Universitária, 
CEP 50670-420, Recife, PE, Brazil
E-mail: josevalterjsilvajr@gmail.com
Received: 15 July 2018
Accepted: 17 July 2018
This is an open-access article distributed under the 
terms of the Creative Commons Attribution License.
Dengue in Brazil in 2017: what happened?
Dear Editor
Brazil is a dengue-endemic country and over the years has been facing several 
outbreaks caused by different serotypes of the virus. More recently, between 2015 
and 2016, the country reported an annual average of 1,586,155 probable cases1,2. 
However, in 2017, two or four years after the probable introduction of Zika virus 
(ZIKV)3,4, Brazil experienced a decrease in dengue fever to 252,054 cases, besides 
a reduction in the number of severe dengue and deaths2.
In 2017, the number of Zika cases also declined in Brazil in comparison to 
the previous year, about 92% reduction2. The decrease in Zika cases influenced 
by anti-ZIKV herd immunity has already been previously discussed5,6. However, 
regarding dengue disease, the causes of this decline are still not fully understood. 
Indeed, as shown below, the current data on herd immunity, cross-reactions between 
Dengue virus (DENV) and ZIKV, mosquito ecology, vector control measures and 
environmental factors are not sufficient to explain the dengue scenario in 2017.
First, the anti-dengue herd immunity does not seem to explain the decline in 
dengue cases in 2017. In Brazil, between 2009 and 2016, DENV-1 was the most 
prevalent serotype7. In the year 2015, for instance, the prevalence of DENV-1, 
DENV-2, DENV-3 and DENV-4 was 94.1, 0.7, 0.4 and 4.8%, respectively8. In the 
same way, in 2016 (up to epidemiological week 4), prevalences were 97.24, 0.69, 
0.69 and 1.38% to DENV-1, DENV-2, DENV-3 and DENV-4, respectively8. In 2017, 
however, serotype 2 was the most prevalent (54.3%)7. This very low prevalence of 
DENV-2 in the years 2015 and 2016 reduces the possibility that dengue cases have 
fallen in 2017 due to the anti-DENV-2 herd immunity.
In another perspective, the studies on cross-reactivity between DENV and ZIKV 
also do not explain the fall in dengue cases in 2017. Regarding anti-ZIKV immunity 
in relation to DENV infections, to our knowledge, there are only two reports on 
the in vivo modulation of anti-ZIKV antibodies with respect to DENV infection: 
Stettler et al.9 and George et al.10 demonstrated the increase of DENV-2 infection 
by anti-ZIKV antibodies in mice and rhesus monkeys. Interestingly, DENV-2, as 
commented above, was the most prevalent serotype in 2017 in Brazil8. In this way, 
it would be expected that the herd immunity against ZIKV would increase, but not 
decrease the number of dengue cases in Brazil. 
In Salvador, Brazil, Ribeiro et al.11 suggested that the decrease in dengue cases 
between 2015 and 2017 would be the result of the cross-herd immunity to ZIKV. 
Although Ribeiro et al.11 did not mention the circulating DENV serotypes in 
Salvador during the study, data from the Brazilian Ministry of Health demonstrated 
that the serotypes identified in Bahia in 2015 were DENV-1 (96.3%) and DENV-4 
(3.7%)12 (data for 2016 and 2017 were not found). 
In addition to the immunological explanations, vector-related factors should also 
be considered. About this, the increase of confirmed cases of chikungunya between 
2016 and 2017, from 151,3181 to 151,9662, weakens the hypothesis of the fall of 
DENV infection in 2017 as a consequence of vector control measures or environmental 
factors. Since 2015, DENV, ZIKV and Chikungunya virus (CHIKV) circulate in Brazil 
and Aedes aegypti coinfection with these arboviruses could favor the transmission 
of a specific virus, reflecting the change in the epidemiological pattern. However, 
when the vector was coinfected with two or three arboviruses (DENV-CHIKV and 
DENV-ZIKV) no advantages were observed for any of these viruses13-15. 
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Therefore, despite the progress on cross-reactivity 
studies between flaviviruses and on the mosquito ecology, 
we believe that a more detailed analysis of the variables 
involved in the DENV-ZIKV interaction is required. We 
recognize that arboviruses outbreaks result from a complex 
interaction among several factors, such as environmental 
determinants, mosquito ecology, viral genetics, behavior 
and immunological background of the population5,6,16-19. 
However, it is important that the immunological studies are 
redesigned and carried out taking into account the multiple 
variables capable of influencing  the cross-reaction 
between DENV and ZIKV: a) existence of different 
DENV serotypes, mainly DENV-4, which forms a group 
considerably distant from DENV-1, -2 and -320; b) animal 
model for in vivo studies; c) naïve populations or with 
history of previous flaviviruses infections; d) coinfection 
or immunity to other flaviviruses (e.g. Yellow fever virus 
and West Nile virus); e) existence of antibodies against 
conserved or flavivirus-specific regions of the envelope 
protein; f) genetic diversity of individuals’ immune 
responses; g) intrinsic factors related to the viruses, such as 
possible mutations, mainly in the gene sequence coding for 
the envelope. Finally, we argue that only by narrowing the 
gap between laboratory assays and natural infections it will 
be possible to make substantiated interpretations on the 
epidemiology of the areas with flaviviruses co-circulation.
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